• Omkar Soni
• Harshavardhan Sature
• Akash Jadhav
• Dr. Vivekkumar Redasani

Metformin, a first-line biguanide anti-diabetic drug, continues to dominate India’s diabetes treatment market due to its cost-effectiveness, well-established efficacy, and strong safety profile. This updated review provides a comprehensive market analysis of metformin in India, incorporating the latest sales data (2023–2024), emerging trends, competitive landscape, and regulatory updates. With India’s diabetic population exceeding 101 million (IDF 2023) [10], metformin remains the most prescribed oral anti-diabetic, contributing significantly to the ₹25,000+ crore anti-diabetic drug market. The paper explores key players, pricing dynamics, prescription trends, and future growth drivers, including fixed-dose combinations (FDCs) and government healthcare initiatives.

Metformin, Diabetes treatment market, India, Cost-effectiveness, Safety profile, Market analysis, Sales data (2023–2024), Competitive landscape, Regulatory updates, Diabetic population (101 million), Oral anti-diabetic, Fixed-dose combinations (FDCs), Government healthcare initiatives, Pricing dynamics, Prescription trends, IDF 2023, ₹25,000+ crore market, First-line treatment, Biguanide, Growth drivers

"Market Analysis of Metformin as an Antidiabetic Agent in India", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 5, page no.k197-k202, May-2025, Available :http://www.jetir.org/papers/JETIR2505B12.pdf

"Market Analysis of Metformin as an Antidiabetic Agent in India", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 5, page no. ppk197-k202, May-2025, Available at : http://www.jetir.org/papers/JETIR2505B12.pdf